CL2021001248A1 - Métodos de tratamiento para la fibrosis quística - Google Patents

Métodos de tratamiento para la fibrosis quística

Info

Publication number
CL2021001248A1
CL2021001248A1 CL2021001248A CL2021001248A CL2021001248A1 CL 2021001248 A1 CL2021001248 A1 CL 2021001248A1 CL 2021001248 A CL2021001248 A CL 2021001248A CL 2021001248 A CL2021001248 A CL 2021001248A CL 2021001248 A1 CL2021001248 A1 CL 2021001248A1
Authority
CL
Chile
Prior art keywords
cystic fibrosis
treatment methods
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
CL2021001248A
Other languages
English (en)
Inventor
Mark Thomas Miller
Jeremy J Clemens
Thomas Cleveland
Timothy Richard Coon
Jason Mccartney
Jinglan Zhou
Ruah Sara Sabina Hadida
Goor Fredrick Van
Prasuna Paraselli
Weichao George Chen
Corey Don Anderson
Bryan Frieman
Fabrice Pierre
Sara E Swift
David M Altshuler
Peter Grootenhuis (Fallecido)
Brian J Hare
Reshma Kewalramani
Sarah M Robertson
Patrick R Sosnay
Bartlomiej Borek
Tim Young
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68808572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001248(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CL2021001248A1 publication Critical patent/CL2021001248A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta solicitud describe métodos para tratar la fibrosis quística o una enfermedad mediada por CFTR que comprende administrar el Compuesto I o una sal farmacéuticamente aceptable de este. La solicitud describe además composiciones farmacéuticas que comprenden el Compuesto I o una sal farmacéuticamente aceptable de este y que comprende opcionalmente uno o más agentes moduladores de CFTR adicionales.
CL2021001248A 2018-11-14 2021-05-12 Métodos de tratamiento para la fibrosis quística CL2021001248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862767202P 2018-11-14 2018-11-14

Publications (1)

Publication Number Publication Date
CL2021001248A1 true CL2021001248A1 (es) 2021-11-26

Family

ID=68808572

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001248A CL2021001248A1 (es) 2018-11-14 2021-05-12 Métodos de tratamiento para la fibrosis quística

Country Status (22)

Country Link
US (1) US20220047564A1 (es)
EP (2) EP3880197B1 (es)
AU (1) AU2019381750A1 (es)
BR (1) BR112021009145A2 (es)
CA (1) CA3123578A1 (es)
CL (1) CL2021001248A1 (es)
CO (1) CO2021007447A2 (es)
DK (1) DK3880197T3 (es)
EA (1) EA202191361A1 (es)
ES (1) ES2943126T3 (es)
FI (1) FI3880197T3 (es)
HR (1) HRP20230272T1 (es)
HU (1) HUE061686T2 (es)
IL (1) IL282988A (es)
LT (1) LT3880197T (es)
MA (1) MA54227B1 (es)
MD (1) MD3880197T2 (es)
PL (1) PL3880197T3 (es)
PT (1) PT3880197T (es)
RS (1) RS64192B1 (es)
SI (1) SI3880197T1 (es)
WO (1) WO2020102346A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3082444A1 (en) * 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
MA51828B1 (fr) 2018-02-15 2022-11-30 Vertex Pharma Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé
TW202120517A (zh) * 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
EP4013760A1 (en) * 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1458693A4 (en) 2001-11-14 2005-02-09 Teva Pharma Amorphous and crystalline forms of losartan potassium and method for making same
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
CN102231990B (zh) 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
AR073709A1 (es) 2008-09-29 2010-11-24 Vertex Pharma Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
ES2845449T3 (es) 2010-03-25 2021-07-26 Vertex Pharma Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida
RU2592368C2 (ru) 2010-04-07 2016-07-20 Вертекс Фармасьютикалз Инкорпорейтед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ 3-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНУЮ КИСЛОТУ, И ИХ ВВЕДЕНИЕ
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
CN103153286A (zh) 2010-08-27 2013-06-12 沃泰克斯药物股份有限公司 药物组合物及其施用
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
AU2013337730B2 (en) 2012-11-02 2018-06-14 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR mediated diseases
RS57476B9 (sr) 2014-04-15 2021-10-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
EP3352757B1 (en) 2015-09-21 2023-08-16 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
PL3519401T3 (pl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator mukowiscydozowego przezbłonowego regulatora przewodnictwa, kompozycje farmaceutyczne, sposoby leczenia i proces wytwarzania modulatora
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
WO2019018353A1 (en) * 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
US11517564B2 (en) * 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MA51828B1 (fr) * 2018-02-15 2022-11-30 Vertex Pharma Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé

Also Published As

Publication number Publication date
EP4218754A3 (en) 2023-08-16
EA202191361A1 (ru) 2021-08-11
PT3880197T (pt) 2023-05-09
FI3880197T3 (fi) 2023-05-04
DK3880197T3 (da) 2023-03-27
CO2021007447A2 (es) 2021-12-10
WO2020102346A1 (en) 2020-05-22
HRP20230272T1 (hr) 2023-04-28
SI3880197T1 (sl) 2023-04-28
RS64192B1 (sr) 2023-06-30
US20220047564A1 (en) 2022-02-17
ES2943126T3 (es) 2023-06-09
IL282988A (en) 2021-06-30
MA54227A (fr) 2021-09-22
MA54227B1 (fr) 2023-03-31
PL3880197T3 (pl) 2023-07-31
HUE061686T2 (hu) 2023-08-28
BR112021009145A2 (pt) 2021-08-10
LT3880197T (lt) 2023-05-10
MD3880197T2 (ro) 2023-08-31
EP3880197A1 (en) 2021-09-22
EP4218754A2 (en) 2023-08-02
EP3880197B1 (en) 2023-02-22
AU2019381750A1 (en) 2021-06-24
CA3123578A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
CO2021007447A2 (es) Métodos de tratamiento para la fibrosis quística
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
PE20220170A1 (es) Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
CO2019006865A2 (es) Nuevos derivados de fenilo
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112022003434A2 (pt) Composição de liberação retardada de niclosamida e uso antiviral da mesma
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
AR119159A1 (es) Tratamientos de angioedema
CL2022001314A1 (es) Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
BR112022001514A2 (pt) Composição farmacêutica multicamada e processo para a preparação de uma composição farmacêutica
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
UY36331A (es) Composición farmacéutica sólida que comprende amlodipina y losartán
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
AU2015328044A8 (en) Pharmaceutical composition comprising Aspirin, Metformin, and Serotonin with non-ionic surfactant
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
AR117258A1 (es) Combinación de fármacos con gran actividad para el tratamiento del virus de la hepatitis c